Hood River Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Hood River Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.3M	Buy	968,996 +61,584	+7%	+$2.29M	0.26%	104
2026 Q1	$33M	Buy	907,412 +10,009	+1%	+$447K	0.33%	92
2025 Q4	$41.8M	Buy	897,403 +14,399	+2%	+$641K	0.46%	79
2025 Q3	$36.8M	Sell	883,004 -5,466	-0.6%	-$175K	0.43%	75
2025 Q2	$25.6M	Buy	888,470 +15,835	+2%	+$489K	0.36%	94
2025 Q1	$29.3M	Buy	872,635 +21,235	+2%	+$793K	0.5%	80
2024 Q4	$43.5M	Buy	851,400 +16,488	+2%	+$922K	0.64%	64
2024 Q3	$42.7M	Buy	834,912 +424,570	+103%	+$21.9M	0.69%	58
2024 Q2	$18.4M	Buy	+410,342	New	+$18.9M	0.38%	85

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hood River Capital Management's CRNX Position: Q2 2026 in Review

Hood River Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 6.8% in Q2 2026, buying an estimated $2.29M and bringing the position to 968,996 shares worth $36.3M. The position accounts for 0.26% of the portfolio, ranked #104.

Hood River Capital Management first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $43.5M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Hood River Capital Management held 968,996 shares of Crinetics Pharmaceuticals worth $36.3M as of Q2 2026.
Hood River Capital Management bought 61,584 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.29M.
Crinetics Pharmaceuticals made up 0.26% of Hood River Capital Management's portfolio in Q2 2026, its #104 holding.
Hood River Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Hood River Capital Management's Crinetics Pharmaceuticals position peaked at $43.5M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.